Featured Research

from universities, journals, and other organizations

Study Finds Best Use Of Insulin As Diabetes Progresses

Date:
October 26, 2009
Source:
University of Oxford
Summary:
A large-scale trial in diabetes patients has provided new evidence on how best to add insulin to standard drugs to control blood sugar levels as type 2 diabetes progresses.

A large-scale trial in diabetes patients has provided new evidence on how best to add insulin to standard drugs to control blood sugar levels as type 2 diabetes progresses.

The University of Oxford research was published in the New England Journal of Medicine to coincide with presentation of the final trial results at the World Diabetes Congress in Montreal, Canada.

Patients who added insulin, either through once-a-day (basal) insulin injections or three injections at mealtimes, to their oral anti-diabetes drugs showed better control of their blood sugar levels than those adding twice daily insulin injections.

Those starting with a single insulin injection each day also had fewer hypoglycaemic episodes (when blood sugar levels are too low) and gained less weight.

'Type 2 diabetes is a progressive condition with the majority of patients eventually requiring insulin therapy,' says Professor Rury Holman, principal investigator of the study and director of the Diabetes Trials Unit at Oxford University. 'This large-scale study strengthens guidelines recommending adding a basal insulin to oral agents when glycaemic targets are not met.'

Improved control of blood sugar levels is known to reduce the risk of complications in type 2 diabetes, such as kidney failure and loss of vision from eye disease. As type 2 diabetes progresses, the standard oral therapy will typically need to be escalated repeatedly over time.

Eventually, the majority of patients will require insulin but there remains uncertainty as to which regimen of insulin injections should be used when oral drugs become insufficient. There is no clear consensus about whether to start with insulin therapy three times a day with meals, injections twice a day, or a long-acting once-a-day insulin injection.

The researchers set out to find which pattern of treatment resulted in the best control of blood sugar levels. Their three-year, randomised controlled trial compared different insulin regimens in 708 patients with type 2 diabetes whose current doses of anti-diabetic drugs were not proving sufficient.

During the first year, the patients were randomised to one of the three insulin courses. During the second and third years, those who were still not achieving their glucose targets were moved to more complex insulin regimens.

Dr Jonathan Levy, lead clinician at the Oxford Centre for Diabetes, Endocrinology and Metabolism and co-principal investigator said: 'Starting with a basal insulin and adding a mealtime insulin if required provided the best combination of effectiveness, safety and treatment satisfaction'.

'These results will help patients and healthcare professionals in routine clinical practice to decide which treatment is most suitable for the individual,' added Dr Andrew Farmer, co-principal investigator at the Department of Primary Health Care.

Novo Nordisk and Diabetes UK provided funding for the study.


Story Source:

The above story is based on materials provided by University of Oxford. Note: Materials may be edited for content and length.


Cite This Page:

University of Oxford. "Study Finds Best Use Of Insulin As Diabetes Progresses." ScienceDaily. ScienceDaily, 26 October 2009. <www.sciencedaily.com/releases/2009/10/091025205419.htm>.
University of Oxford. (2009, October 26). Study Finds Best Use Of Insulin As Diabetes Progresses. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2009/10/091025205419.htm
University of Oxford. "Study Finds Best Use Of Insulin As Diabetes Progresses." ScienceDaily. www.sciencedaily.com/releases/2009/10/091025205419.htm (accessed August 22, 2014).

Share This




More Health & Medicine News

Friday, August 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins